Brief: ADC Therapeutics - Expected Cash Runway Into Mid-2025
07/11/2023 12:18
Nov 7 (Reuters) - ADC Therapeutics SA ADCT.N :
* ADC THERAPEUTICS SA - EXPECTED CASH RUNWAY INTO MID-2025
* ADC THERAPEUTICS SA - CONTINUED DECREASE IN TOTAL
OPERATING
EXPENSES EXPECTED IN FULL YEAR 2023 AND 2024 AS COMPARED TO 2022
Source text for Eikon: ID:nGNX4c5y75
Further company coverage: ADCT.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on ADC Therapeutics SA
See all newsADC Therapeutics plunges after patient deaths in blood cancer drug trial
ADC Therapeutics falls on higher rates of serious side-effects in cancer trial
Switzerland's ADC Therapeutics beats Q1 revenue estimates
Switzerland's ADC Therapeutics posts smaller‑than‑expected Q4 net loss on lower R&D spend
Brief: ADC Therapeutics Q4 Income From Operations USD -17.919 Million Vs. IBES Estimate USD -30.1 Million